Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform the treatment of autoimmune diseases and cancer by developing allogeneic, iPSC-derived cell therapies.
PRESS RELEASES + EVENTS
view all
November 13, 2025
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug…
November 13, 2025
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose…
About us
We are building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases and cancer.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
